Sunday, October 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· May 24, 2026

Here's the One Thing New Fed Chair Kevin Warsh Could Do That Would Actually Crash the Stock Market

View original at nasdaq.com
Here's the One Thing New Fed Chair Kevin Warsh Could Do That Would Actually Crash the Stock Market Key Points Several actions Warsh could take may be potentially problematic for stocks, but not catastrophic…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • He is calling for regime change at the Federal Reserve

    60% confidence
  • Stock Advisor's total average return is 986%, outperforming the S&P 500's 208%

    60% confidence
  • Warsh could be President Trump's sock puppet, undermining the Fed's political independence

    60% confidence
  • If Warsh is viewed as making ill-advised monetary policy decisions to appease President Trump, panic selling across asset classes could occur

    60% confidence
  • His credibility as Fed Chair is the most important thing to the institution and to the successful conduct of policy

    60% confidence
  • Warsh has been viewed as an inflation hawk throughout his career

    60% confidence
  • The central bank should find new comfort in working without applause and without the audience at the edge of its seats

    60% confidence
  • If the U.S. dollar begins to sink, it could signal major trouble for the bond and stock markets

    60% confidence
  • Warsh favors using the trimmed mean inflation rate rather than the PCE inflation rate

    60% confidence
  • A stock or bond market crash is not likely under Warsh's leadership at the Fed, but some of his moves could increase volatility

    60% confidence
  • Monetary policy independence is essential

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com